Amarin Corporation PLC
NASDAQ:AMRN
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.5486
  • TODAY'S CHANGE (%)
    0.0237 (4.5151%)
  • Bid / Lots
    0.5498/ 1
  • Ask / Lots
    0.5500/ 10
  • Open / Previous Close
    0.5300 / 0.5249
  • Day Range
    0.5205
    0.5600
  • 52 Week Range
    0.4565
    1.3700
  • Volume
    1,372,809

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
AMRN
Amarin Corporation PLC
215.9M
-5.7x
---
CHRS
Coherus BioSciences Inc
126.7M
-12.2x
---
VYGR
Voyager Therapeutics Inc
296.1M
9.6x
---
DNA
Ginkgo Bioworks Holdings Inc
378.8M
-0.6x
---
AMLX
Amylyx Pharmaceuticals Inc
355.8M
-1.4x
---
RVNC
Revance Therapeutics Inc
402.8M
-2.0x
---
As of 2024-11-22

Company Information

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Contact Information

Headquarters
Gemini House, Bartholomews WalkDUBLIN, Ireland FK7 9JQ
Phone
---
Fax
---

Executives

Non-Executive Independent Chairman of the Board
Odysseas Kostas
President, Chief Executive Officer, Director
Aaron Berg
President - Research and Development, Executive Vice President, Chief Scientific Officer
Stephen Ketchum
Executive Vice President, Chief Legal and Compliance Officer, Secretary
Jonathan Provoost
Non-Executive Independent Director
Patrice Bonfiglio

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$215.9M
Revenue (TTM)
$241.0M
Shares Outstanding
411.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.87
EPS
$-0.10
Book Value
$1.35
P/E Ratio
-5.7x
Price/Sales (TTM)
0.9
Price/Cash Flow (TTM)
---
Operating Margin
-18.30%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.